Skip to main content
Log in
Cancer Immunology, Immunotherapy
Publishing model:
Open access

How to publish with us

Publishing options

All articles published by Cancer Immunology, Immunotherapy are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers.

Benefits of open access

Publishing open access offers a number of benefits, including greater reach and readership for your work:

  • Cited more

    1.6x more citations of OA articles than non-OA articles across all subjects

  • Downloaded more

    4x more downloads of OA articles than non-OA articles

  • Greater impact

    2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions

Open access also enables compliance with many major funder policies internationally. Find out more about benefits of open access.

Fees and Funding

Article processing charges (APC)

Authors who publish open access in Cancer Immunology, Immunotherapy are required to pay an article processing charge (APC). The APC price will be determined from the date on which the article is accepted for publication.

The current APC, subject to VAT or local taxes where applicable, is:

£2790.00 / $4390.00 / €3390.00

Visit our open access support portal and our Journal Pricing FAQs for further information.

Open access funding

Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.

Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.

Springer Nature offers APC waivers and discounts for articles published in our fully open access journals whose corresponding authors are based in the world’s lowest income countries (see our APC waivers and discounts policy for further information). Requests for APC waivers and discounts from other authors will be considered on a case-by-case basis, and may be granted in cases of financial need (see our open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.

Creative Commons licences

Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles.

Cancer Immunology, Immunotherapy articles are published open access under a CC BY-NC-ND (Creative Commons Attribution Non-Commercial No Derivatives 4.0 International licence) or CC BY (Creative Commons Attribution 4.0 International licence) licence.

  • CC BY-NC-ND: The article can be shared for non-commercial purposes as long as the authors are credited. Permission is needed for commercial re-use or sharing adapted and derivative versions.
  • CC BY: The article may be shared and adapted for any purpose, including commercially, so long as the authors are credited.

You may also wish to find out about licence variations that are available to meet funder and institutional OA licence requirements. Learn more in our guide to licensing, copyright and author rights for journal articles.

Navigation